Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 9
2004 9
2005 14
2006 17
2007 16
2008 14
2009 25
2010 42
2011 43
2012 47
2013 47
2014 53
2015 70
2016 67
2017 78
2018 81
2019 110
2020 121
2021 163
2022 145
2023 170
2024 58

Text availability

Article attribute

Article type

Publication date

Search Results

1,249 results

Results by year

Filters applied: . Clear all
Page 1
Research Progress on the Pathogenesis of Knee Osteoarthritis.
Du X, Liu ZY, Tao XX, Mei YL, Zhou DQ, Cheng K, Gao SL, Shi HY, Song C, Zhang XM. Du X, et al. Orthop Surg. 2023 Sep;15(9):2213-2224. doi: 10.1111/os.13809. Epub 2023 Jul 12. Orthop Surg. 2023. PMID: 37435789 Free PMC article. Review.
A global study for acute myeloid leukemia with RARG rearrangement.
Zhu HH, Qin YZ, Zhang ZL, Liu YJ, Wen LJ, You MJ, Zhang C, Such E, Luo H, Yuan HJ, Zhou HS, Liu HX, Xu R, Li J, Li JH, Hao JP, Jin J, Yu L, Zhang JY, Liu LP, Zhang LP, Huang RB, Shen SH, Gao SJ, Wang W, Yan XJ, Zhang XY, Du X, Chu XX, Yu YF, Wang Y, Mi YC, Lu Y, Cai Z, Su Z, Taussig DC, MacMahon S, Ball ED, Wang HY, Welch JS, Yin CC, Borthakur G, Sanz MA, Kantarjian HM, Huang JY, Hu J, Chen SN. Zhu HH, et al. Among authors: du x. Blood Adv. 2023 Jul 11;7(13):2972-2982. doi: 10.1182/bloodadvances.2022008364. Blood Adv. 2023. PMID: 36799929 Free PMC article.
Validation of the imatinib-therapy failure model.
Zhang X, Gale RP, Liu B, Huang J, Zhang Y, Du X, Weng J, Li W, Xu N, Liu X, Chen C, Lin H, Li G, Liang R, Liu Z, Wang X, Zhang Y, Han Y, Liu C, Hu J, Lin L, Yang W, Liu Z, Meng L, Tu C, Zheng C, Zhou Z, Bai Y, Qiu H, Chen S, Li F, Guo J, Liu Z, Sun H, Zhou L, Feng R, Sun X, Huang X, Jiang Q. Zhang X, et al. Among authors: du x. Leukemia. 2023 May;37(5):1166-1169. doi: 10.1038/s41375-023-01875-3. Epub 2023 Mar 27. Leukemia. 2023. PMID: 36973351 No abstract available.
Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial.
Jin H, Zhang Y, Yu S, Du X, Xu N, Shao R, Lin D, Chen Y, Xiao J, Sun Z, Deng L, Liang X, Zhang H, Guo Z, Dai M, Shi P, Huang F, Fan Z, Yin Z, Xuan L, Lin R, Jiang X, Yu G, Liu Q. Jin H, et al. Among authors: du x. J Hematol Oncol. 2023 Apr 29;16(1):42. doi: 10.1186/s13045-023-01437-1. J Hematol Oncol. 2023. PMID: 37120593 Free PMC article. Clinical Trial.
The Roles of 2-Hydroxyglutarate.
Du X, Hu H. Du X, et al. Front Cell Dev Biol. 2021 Mar 26;9:651317. doi: 10.3389/fcell.2021.651317. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 33842477 Free PMC article. Review.
Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial.
Jiang Q, Li Z, Qin Y, Li W, Xu N, Liu B, Zhang Y, Meng L, Zhu H, Du X, Chen S, Liang Y, Hu Y, Liu X, Song Y, Men L, Chen Z, Niu Q, Wang H, Lu M, Yang D, Zhai Y, Huang X. Jiang Q, et al. Among authors: du x. J Hematol Oncol. 2022 Aug 18;15(1):113. doi: 10.1186/s13045-022-01334-z. J Hematol Oncol. 2022. PMID: 35982483 Free PMC article. Clinical Trial.
1,249 results